Yüklüyor......
Population Pharmacokinetic Modeling of Secukinumab in Patients With Moderate to Severe Psoriasis
Secukinumab is a human monoclonal antibody with demonstrated efficacy for moderate to severe psoriasis; it binds to and neutralizes interleukin (IL)‐17A. The pharmacokinetic (PK) parameters of secukinumab were best described by a 2‐compartment model. Only weight was included in the final model, as o...
Kaydedildi:
| Yayımlandı: | J Clin Pharmacol |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5485066/ https://ncbi.nlm.nih.gov/pubmed/28273356 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.876 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|